It was January 2012, Isaac dribbled the ball; shot it through the hoop, swish! This was a simple moment the 15-year-old athlete who once participated in cross country, soccer and basketball, thought he’d never experience again. Ten months earlier, Isaac was diagnosed with a brain tumor. He became a patient at St. Jude Children’s Research Hospital® and through extensive treatment and care, his cancer is in remission and he is able to play the sports he loves.
Chili’s® Grill & Bar is helping St. Jude patients like Isaac enjoy their own special, everyday moments through the brand’s ninth annual Create-A-Pepper to Fight Childhood Cancer campaign. Participating Chili’s restaurants nationwide and in Puerto Rico are joining in the fight against childhood cancer and other life-threatening diseases. September is National Childhood Cancer Awareness month and through Sept. 26, Chili’s guests can help the cause by donating at their local restaurants and online.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57540-chili-s-create-a-pepper-for-st-jude
Captain Underpants and the Terrifying Return of Tippy Tinkletrousers Trailer
Tra-la-laaa! Captain Underpants is back in an all-new epic adventure from Dav Pilkey!
http://www.pilkey.com and http://www.scholastic.com/captainunderpants children/comedy
Mimi’s Cafe® is celebrating the “lift off” of “Mimi’s for Miracles,” a month-long national awareness and fundraising campaign benefitting Children’s Miracle Network Hospitals. And Friday, July 6, on Mimi’s Muffins for Miracles Day, guests can enjoy a FREE Strawberry Shortcake muffin, Mimi’s newest creation, with a donation and any purchase at Mimi’s Cafe restaurants.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57022-mimi-s-cafe-muffins-for-miracles-children-s-miracle-network-hospitals
St. Jude Children’s Research Hospital is launching a new series of public service announcements (PSAs) to help raise awareness and deepen the understanding of the hospital’s lifesaving mission through real St. Jude heroes – its patients and families. St. Jude has not produced national PSAs since 2003 and timed this new multichannel campaign to coincide with the hospital’s 50th anniversary.
The PSAs share St. Jude moments through patients and families like 10-year-old Angiel. Angiel and her mom Damaris were planning a trip to Africa for a family reunion when she was diagnosed with osteosarcoma, a type of bone cancer that produced tumors in both of Angiel’s legs. Today, thanks to St. Jude doctors, Angiel can still look forward to visiting family in a foreign land one day. Angiel’s story is just one of several patients featured in the PSAs.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/stjude/46749/
To speed progress against cancer and other diseases, the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project today announced the largest-ever release of comprehensive human cancer genome data for free access by the global scientific community. The amount of information released more than doubles the volume of high-coverage, whole genome data currently available from all human genome sources combined. This information is valuable not just to cancer researchers, but also to scientists studying almost any disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52993-st-jude-childrens-research-hospital-comprehensive-human-cancer-genome-data
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
The beach. The boardwalk. The ghosts… All Sara wants is to be “normal,” but her paranormal abilities make that difficult. And, now that she’s moving across the country to an old New Jersey shore town filled with ghosts, things are getting worse. Because this time, she doesn’t just see the ghosts, she can hear them, too. Find out more at http://bit.ly/SaraNormal Childrens
Researchers have identified the first gene mutation associated with a chronic and often fatal form of neuroblastoma that typically strikes adolescents and young adults. The finding provides the first clue about the genetic basis of the long-recognized but poorly understood link between treatment outcome and age at diagnosis.
The study involved 104 infants, children and young adults with advanced neuroblastoma, a cancer of the sympathetic nervous system. Investigators discovered the ATRX gene was mutated only in patients age 5 and older. The alterations occurred most often in patients age 12 and older. These older patients were also more likely than their younger counterparts to have a chronic form of neuroblastoma and die years after their disease is diagnosed.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52992-st-jude-pediatric-cancer-genome-project-neuroblastoma-research
Best childrens books http://buttonthemouse.com/Books Button Goes to School. Once upon a time, two little mice, Button and his mama, lived in a little house under the haystack on a small farm in the country. Button was young but almost old enough to go to school. Soon this day would come. http://www.youtube.com/watch?v=HDXvFPxzvUA
Doctors at Children’s Hospital Boston are just another step closer to securing a cure for sickle cell disease thanks to a little help from some superstar friends. More than $1 million was raised in support of their research efforts on Sunday, January 15 during the “Play Without Pain: Children’s Sickle Cell Benefit,” a partnership with international megastar Celine Dion, Caesars Entertainment, AEG Live and Children’s Hospital Boston. Held at Caesars Palace, the evening included a performance of Celine Dion’s glamorous show directed by Grammy Awards producer Ken Ehrlich, including a touching tribute to sickle cell victims during her rendition of Billy Joel’s “Lullabye.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/54153-celine-dion-play-without-pain-children-s-sickle-cell-benefit
New findings from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP) have helped identify the mechanism that makes the childhood eye tumor retinoblastoma so aggressive. The discovery explains why the tumor develops so rapidly while other cancers can take years or even decades to form.
The finding also led investigators to a new treatment target and possible therapy for the rare childhood tumor of the retina, the light-sensing tissue at the back of the eye. The study appears in the January 11 advance online edition of the scientific journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46767-st-jude-genome-project-treatment-childhood-eye-tumor-retinoblastoma
Researchers have discovered that a subtype of leukemia characterized by a poor prognosis is fueled by mutations in pathways distinctly different from a seemingly similar leukemia associated with a much better outcome. The findings from the St. Jude Children’s Research Hospital — Washington University Pediatric Cancer Genome Project (PCGP) highlight a possible new strategy for treating patients with this more aggressive cancer.
The work provides the first details of the genetic alterations fueling a subtype of acute lymphoblastic leukemia (ALL) known as early T-cell precursor ALL (ETP-ALL). The results suggest ETP-ALL has more in common with acute myeloid leukemia (AML) than with other subtypes of ALL. The study appears in the January 12 edition of the journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46768-st-jude-cancer-genome-sequencing-project-combat-aggressive-leukemia
